Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the target of some unusual options trading on Thursday. Stock investors bought 52,856 call options on the company. This is an increase of 134% compared to the typical volume of 22,543 call options.
Analysts Set New Price Targets
A number of brokerages have recently weighed in on RXRX. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price on the stock. Needham & Company LLC restated a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $7.25.
View Our Latest Report on Recursion Pharmaceuticals
Insider Buying and Selling
In related news, insider Najat Khan sold 36,599 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider directly owned 668,197 shares of the company's stock, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.43% of the stock is owned by insiders.
Institutional Trading of Recursion Pharmaceuticals
A number of hedge funds have recently bought and sold shares of RXRX. Centaurus Financial Inc. raised its stake in shares of Recursion Pharmaceuticals by 32.0% during the 2nd quarter. Centaurus Financial Inc. now owns 14,665 shares of the company's stock worth $74,000 after purchasing an additional 3,555 shares during the period. Liontrust Investment Partners LLP increased its holdings in Recursion Pharmaceuticals by 18.0% during the second quarter. Liontrust Investment Partners LLP now owns 702,386 shares of the company's stock worth $3,554,000 after buying an additional 107,331 shares during the last quarter. Hudson Bay Capital Management LP raised its position in Recursion Pharmaceuticals by 18.0% in the second quarter. Hudson Bay Capital Management LP now owns 150,000 shares of the company's stock worth $759,000 after acquiring an additional 22,930 shares during the period. Headlands Technologies LLC boosted its stake in Recursion Pharmaceuticals by 20.2% in the second quarter. Headlands Technologies LLC now owns 199,415 shares of the company's stock valued at $1,009,000 after acquiring an additional 33,565 shares during the last quarter. Finally, Sender Co & Partners Inc. purchased a new position in Recursion Pharmaceuticals in the second quarter valued at about $121,000. 89.06% of the stock is currently owned by institutional investors.
Recursion Pharmaceuticals Stock Down 1.2%
NASDAQ RXRX traded down $0.06 on Monday, reaching $4.77. The company had a trading volume of 20,622,313 shares, compared to its average volume of 24,015,215. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The company's fifty day moving average is $5.34 and its 200 day moving average is $5.29. Recursion Pharmaceuticals has a 52-week low of $3.79 and a 52-week high of $12.36. The stock has a market capitalization of $2.07 billion, a P/E ratio of -2.68 and a beta of 0.91.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same quarter in the previous year, the company earned ($0.40) EPS. The business's revenue was up 33.3% compared to the same quarter last year. Sell-side analysts anticipate that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
